

IN THE UNITED STATES DISTRICT COURT  
FOR THE SOUTHERN DISTRICT OF NEW YORK

PURDUE PHARMA L.P.,  
THE P.F. LABORATORIES, INC.,  
PURDUE PHARMACEUTICALS L.P.,  
RHODES TECHNOLOGIES,  
BOARD OF REGENTS OF THE UNIVERSITY OF  
TEXAS SYSTEM,  
and GRÜNENTHAL GMBH,

Plaintiffs,

v.

ACTAVIS ELIZABETH LLC,

Defendant.

11 C.A. No. **CIV 2038**



**COMPLAINT**

Plaintiffs Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue  
Pharmaceuticals L.P., Rhodes Technologies, Board of Regents of The University of Texas  
System, and Grünenthal GmbH for their Complaint herein, aver as follows:

**NATURE OF THE ACTION**

1. This is an action for patent infringement arising under the patent laws of  
the United States, Title 35, United States Code.

**THE PARTIES: PLAINTIFFS**

2. Plaintiff Purdue Pharma L.P. (“Purdue Pharma”) is a limited partnership  
organized and existing under the laws of the State of Delaware, having a place of business at One  
Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901-3431. Purdue Pharma is an  
owner of United States Patent Nos. 7,674,799, 7,674,800, and 7,683,072 identified in paragraphs  
15-17 below, an exclusive sublicensee of United States Patent No. 6,488,963 identified in

paragraph 14 below, and an exclusive licensee of United States Patent No. 7,776,314 identified in paragraph 18 below. Purdue Pharma is also the holder of New Drug Application (“NDA”) No. 022272 for the controlled-release oxycodone pain-relief medication OxyContin<sup>®</sup>, and is involved in the sales of OxyContin<sup>®</sup> in the United States.

3. Plaintiff The P.F. Laboratories, Inc. (“P.F. Labs”) is a corporation organized and existing under the laws of the State of New Jersey, having a place of business at 700 Union Boulevard, Totowa, NJ 07512. P.F. Labs is an owner of United States Patent Nos. 7,674,799, 7,674,800, and 7,683,072 identified in paragraphs 15-17 below, and is involved in the manufacture of controlled-release oxycodone pain-relief medication under the brand name OxyContin<sup>®</sup>.

4. Plaintiff Purdue Pharmaceuticals L.P. (“Purdue Pharmaceuticals”) is a limited partnership organized and existing under the laws of the State of Delaware, having a place of business at 4701 Purdue Drive, Wilson, NC 27893. Purdue Pharmaceuticals is an owner of United States Patent Nos. 7,674,799, 7,674,800, and 7,683,072 identified in paragraphs 15-17 below, and is involved in the manufacture of controlled-release oxycodone pain-relief medication under the brand name OxyContin<sup>®</sup>.

5. Plaintiff Rhodes Technologies (“Rhodes”) is a general partnership organized and existing under the laws of the State of Delaware, having a place of business at 498 Washington Street, Coventry, RI 02816. Rhodes is an owner of United States Patent Nos. 7,674,799, 7,674,800, and 7,683,072 identified in paragraphs 15-17 below, and is involved in the manufacture of controlled-release oxycodone pain-relief medication under the brand name OxyContin<sup>®</sup>.

6. Plaintiffs Purdue Pharma, P.F. Labs, Purdue Pharmaceuticals, and Rhodes

are associated companies.

7. Plaintiff Board of Regents of The University of Texas System (“University of Texas”) is an agency organized and existing under the laws of the State of Texas, having an address at 201 West 7th Street, Austin, TX 78701. University of Texas is the owner of United States Patent No. 6,488,963 identified in paragraph 14 below.

8. Plaintiff Grünenthal GmbH (“Grünenthal”) is a corporation organized and existing under the laws of Germany, having an address at 52078 Aachen, Zieglerstrasse 6, Germany. Grünenthal is the owner of United States Patent No. 7,776,314 identified in paragraph 18 below.

#### **THE PARTIES: DEFENDANT**

9. Upon information and belief, Defendant Actavis Elizabeth LLC (“Actavis”) is a limited liability company organized and existing under the laws of the State of Delaware, having its principal place of business at 200 Elmora Avenue, Elizabeth, NJ 07207.

10. Upon information and belief, Actavis is registered as a Pharmacy Establishment in the State of New York by the New York State Department of Education, Office of the Professions. (Registration No. 025892). The Registration has an active status and is valid through February 29, 2012.

#### **JURISDICTION AND VENUE**

11. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201 and 2202.

12. This Court has personal jurisdiction over Actavis because, *inter alia*, Actavis has purposefully availed itself of the rights and benefits of the laws of this State and this Judicial District. Upon information and belief, Actavis does business in this State and this Judicial District, has engaged in continuous and systematic contact with this State and this

Judicial District, and derives substantial revenue from things used or consumed in this State and this Judicial District. Upon information and belief, Actavis engages in the manufacture and sale of a range of pharmaceutical products within and directed to the United States and this Judicial District specifically. Actavis has previously consented to personal jurisdiction in this Judicial District in patent litigation concerning United States Patent Nos. 7,674,799, 7,674,800, and 7,683,072 identified in paragraphs 15-17 below, which suit was based on an earlier ANDA that Actavis submitted to the FDA also directed to generic oxycodone hydrochloride extended release tablets. *See Purdue Pharma L.P. et al. v. Ranbaxy Inc. et al.*, No. 10-civ-3734 (SHS) (S.D.N.Y. May 5, 2010). Further, this Court has personal jurisdiction over Actavis because Actavis is registered as a Pharmacy Establishment in the State of New York by the New York State Department of Education, Office of the Professions. In addition, upon information and belief, Actavis is actively preparing to make the proposed generic copies of OxyContin<sup>®</sup> that are the subject of its Abbreviated New Drug Application (“ANDA”) No. 202434, and to use, sell and offer for sale such generic copies in this State and this Judicial District.

13. Venue is proper in this Judicial District under 28 U.S.C. §§ 1391(b) and (c) and § 1400(b).

#### **THE PATENTS IN SUIT**

14. Plaintiff University of Texas is the lawful owner of all right, title and interest in United States Patent No. 6,488,963 entitled “HOT-MELT EXTRUDABLE PHARMACEUTICAL FORMULATION” (“the ‘963 patent”), including the right to sue and to recover for past infringement thereof. Plaintiff University of Texas granted an exclusive license under the ‘963 patent to Abbott Laboratories, who in turn, granted an exclusive sublicense under that patent to Plaintiff Purdue Pharma. The ‘963 patent is listed in the U.S. Food and Drug Administration’s (“FDA”) “Orange Book” (*Approved Drug Products With Therapeutic*

*Equivalence Evaluation*) as covering OxyContin<sup>®</sup>, which is the subject of approved NDA No. 022272. A copy of the '963 patent is attached hereto as Exhibit A, which was duly and legally issued on December 3, 2002, naming James W. McGinity and Feng Zhang as the inventors.

15. Plaintiffs Purdue Pharma, P.F. Labs, Purdue Pharmaceuticals, and Rhodes are the lawful owners of all right, title and interest in United States Patent No. 7,674,799 entitled "OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE" ("the '799 patent"), including all right to sue and to recover for past infringement thereof, which patent is listed in FDA's Orange Book as covering the drug OxyContin<sup>®</sup>, which is the subject of approved NDA No. 022272. A copy of the '799 patent is attached hereto as Exhibit B, which was duly and legally issued on March 9, 2010, naming Robert Chapman, Lon S. Rider, Qi Hong, Donald Kyle, and Robert Kupper as the inventors.

16. Plaintiffs Purdue Pharma, P.F. Labs, Purdue Pharmaceuticals, and Rhodes are the lawful owners of all right, title and interest in United States Patent No. 7,674,800 entitled "OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE" ("the '800 patent"), including all right to sue and to recover for past infringement thereof, which patent is listed in the FDA's Orange Book as covering the drug OxyContin<sup>®</sup>, which is the subject of approved NDA No. 022272. A copy of the '800 patent is attached hereto as Exhibit C, which was duly and legally issued on March 9, 2010, naming Robert Chapman, Lon S. Rider, Qi Hong, Donald Kyle, and Robert Kupper as the inventors.

17. Plaintiffs Purdue Pharma, P.F. Labs, Purdue Pharmaceuticals, and Rhodes are the lawful owners of all right, title and interest in United States Patent No. 7,683,072 entitled "OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE" ("the '072 patent"), including all right to sue and to recover for past

infringement thereof, which patent is listed in the FDA's Orange Book as covering the drug OxyContin<sup>®</sup>, which is the subject of approved NDA No. 022272. A copy of the '072 patent is attached hereto as Exhibit D, which was duly and legally issued on March 23, 2010, naming Robert Chapman, Lon S. Rider, Qi Hong, Donald Kyle, and Robert Kupper as the inventors.

18. Plaintiff Grünenthal is the lawful owner of all right, title and interest in United States Patent No. 7,776,314 entitled "ABUSE-PROOFED DOSAGE SYSTEM" ("the '314 patent"), including the right to sue and to recover for past infringement thereof. Plaintiff Purdue Pharma is the exclusive licensee of the '314 patent from Grünenthal, with the right to enforce the '314 patent. The '314 patent is listed in the FDA's Orange Book as covering the drug OxyContin<sup>®</sup>, which is the subject of approved NDA No. 022272. A copy of the '314 patent is attached hereto as Exhibit E, which was duly and legally issued on August 17, 2010, naming Johannes Bartholomäus and Heinrich Kugelmann as the inventors.

#### **DEFENDANT'S ANDA**

19. Upon information and belief, Actavis submitted ANDA No. 202434 to the FDA, under § 505(j) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(j)), seeking approval to engage in the commercial manufacture, use, sale, offer for sale or importation of generic oxycodone hydrochloride extended release tablets ("proposed generic copies of OxyContin<sup>®</sup>") based on the Reference Listed Drug ("RLD") OxyContin<sup>®</sup>, which is the subject of approved NDA No. 022272, before the expiration of the '963, '799, '800, '072, and '314 patents.

20. Upon information and belief, ANDA No. 202434 contains a "Paragraph IV" certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) alleging that the '963, '799, '800, '072, and '314 patents, listed in the FDA's Orange Book as covering the drug OxyContin<sup>®</sup>, which is the subject of approved NDA No. 022272, are "invalid, unenforceable or will not be infringed by the commercial manufacture, use, importation, offer for sale or sale of [the proposed generic

copies of OxyContin<sup>®</sup>].”

21. In a letter dated February 15, 2011 addressed to Plaintiffs and received by Plaintiffs Purdue Pharma, P.F. Labs, Purdue Pharmaceuticals, and Rhodes on February 16, 2011, Actavis provided “notice” with respect to its proposed generic copies of OxyContin<sup>®</sup> and the ‘963, ‘799, ‘800, ‘072, and ‘314 patents under 21 U.S.C. § 355(j)(2)(B) (“Notice Letter”).

22. Actavis’s submission of its ANDA was an act of infringement of the ‘963, ‘799, ‘800, ‘072, and ‘314 patents under the United States Patent Law, 35 U.S.C. § 271(e)(2)(A).

23. Upon information and belief, Actavis’s proposed generic copies of OxyContin<sup>®</sup> are covered by one or more claims of the ‘963, ‘799, ‘800, ‘072, and ‘314 patents.

24. Upon information and belief, Actavis’s commercial manufacture, use, sale, and/or offer for sale of the proposed generic copies of OxyContin<sup>®</sup> would infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the ‘963, ‘799, ‘800, ‘072, and ‘314 patents.

25. Upon information and belief, Actavis has been aware of the existence of the ‘963, ‘799, ‘800, ‘072, and ‘314 patents, and has no reasonable basis for believing that the proposed generic copies of OxyContin<sup>®</sup> will not infringe the ‘963, ‘799, ‘800, ‘072, and ‘314 patents, thus rendering the case “exceptional,” as that term is used in 35 U.S.C. § 285.

26. The acts of infringement by Actavis set forth above will cause Plaintiffs irreparable harm for which they have no adequate remedy at law, and will continue unless enjoined by this Court.

WHEREFORE, Plaintiffs pray for judgment:

A. Adjudging that Actavis has infringed the ‘963, ‘799, ‘800, ‘072, and ‘314 patents, and that the commercial sale, offer for sale, use, and/or manufacture of the proposed generic copies of OxyContin<sup>®</sup> described in ANDA No. 202434 would infringe, induce

infringement of, and/or contribute to the infringement of the '963, '799, '800, '072, and '314 patents;

B. Adjudging, pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date of any approval of ANDA No. 202434, under § 505(j) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(j)), to be a date not earlier than the dates of expiration of the '963, '799, '800, '072, and '314 patents plus any additional periods of exclusivity;

C. Preliminarily and permanently enjoining, pursuant to 35 U.S.C. §§ 271(e)(4)(B) and 283 and Rule 65, Fed. R. Civ. P., Actavis, its officers, partners, agents, servants, employees, parents, subsidiaries, divisions, affiliate corporations, other related business entities and all other persons acting in concert, participation, or in privity with them, and their successors and assigns, from any commercial manufacture, use, offer to sell, or sale within the United States, or importation into the United States, of any drug product that infringes the '963, '799, '800, '072, and '314 patents;

D. Declaring this an exceptional case and awarding Plaintiffs their attorneys' fees, as provided by 35 U.S.C. §§ 271(e)(4) and 285; and

E. Awarding Plaintiffs such other and further relief as this Court may deem just and proper.



Dated: March 23, 2011

  
ROPES & GRAY LLP

---

Pablo D. Hendler  
Sona-De

1211 Avenue of the Americas  
New York, NY 10036  
(212) 596-9000  
[pablo.hendler@ropesgray.com](mailto:pablo.hendler@ropesgray.com)  
[sona.de@ropesgray.com](mailto:sona.de@ropesgray.com)

Robert J. Goldman  
1900 University Avenue, 6th Floor  
East Palo Alto, CA 94303  
(650) 617-4000  
[robert.goldman@ropesgray.com](mailto:robert.goldman@ropesgray.com)

*Attorneys for Plaintiffs  
Purdue Pharma L.P.,  
The P.F. Laboratories, Inc.,  
Purdue Pharmaceuticals L.P.,  
Rhodes Technologies, and Board of  
Regents of the University of Texas  
System*

Dated: March 23, 2011

R. KUNSTADT, P.C.



---

Robert M. Kunstadt (RK-7230)  
Ilaria Maggioni (IM-7220)  
875 Sixth Avenue, Suite 1800  
New York, New York 10001  
(212) 398-8881  
[mail@RKunstadtPC.com](mailto:mail@RKunstadtPC.com)

*Of counsel:*

BANNER & WITCOFF, LTD.  
Dale H. Hoscheit  
Joseph M. Skerpon  
Robert F. Altherr  
1100 13<sup>th</sup> Street, NW, Suite 1200  
Washington, DC 20005  
(202) 824-3000  
[dhoscheit@bannerwitcoff.com](mailto:dhoscheit@bannerwitcoff.com)  
[jskerpon@bannerwitcoff.com](mailto:jskerpon@bannerwitcoff.com)  
[raltherr@bannerwitcoff.com](mailto:raltherr@bannerwitcoff.com)

*Attorneys for Plaintiff  
Grünenthal GmbH*